Cargando…

Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin

PURPOSE: Systematic comparison of analysis methods of clinical microdialysis data for impact on target-site drug exposure and response. METHODS: 39 individuals received a 500 mg levofloxacin short-term infusion followed by 24-h dense sampling in plasma and microdialysate collection in interstitial s...

Descripción completa

Detalles Bibliográficos
Autores principales: Busse, David, Schaeftlein, André, Solms, Alexander, Ilia, Luis, Michelet, Robin, Zeitlinger, Markus, Huisinga, Wilhelm, Kloft, Charlotte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994214/
https://www.ncbi.nlm.nih.gov/pubmed/33723793
http://dx.doi.org/10.1007/s11095-021-02994-1
_version_ 1783669706713989120
author Busse, David
Schaeftlein, André
Solms, Alexander
Ilia, Luis
Michelet, Robin
Zeitlinger, Markus
Huisinga, Wilhelm
Kloft, Charlotte
author_facet Busse, David
Schaeftlein, André
Solms, Alexander
Ilia, Luis
Michelet, Robin
Zeitlinger, Markus
Huisinga, Wilhelm
Kloft, Charlotte
author_sort Busse, David
collection PubMed
description PURPOSE: Systematic comparison of analysis methods of clinical microdialysis data for impact on target-site drug exposure and response. METHODS: 39 individuals received a 500 mg levofloxacin short-term infusion followed by 24-h dense sampling in plasma and microdialysate collection in interstitial space fluid (ISF). ISF concentrations were leveraged using non-compartmental (NCA) and compartmental analysis (CA) via (ii) relative recovery correction at midpoint of the collection interval (midpoint-NCA, midpoint-CA) and (ii) dialysate-based integrals of time (integral-CA). Exposure and adequacy of community-acquired pneumonia (CAP) therapy via pharmacokinetic/pharmacodynamic target-attainment (PTA) analysis were compared between approaches. RESULTS: Individual AUC(ISF) estimates strongly varied for midpoint-NCA and midpoint-CA (≥52.3%CV) versus integral-CA (≤32.9%CV) owing to separation of variability in PK parameters (midpoint-CA = 46.5%–143%CV(PK), integral-CA = 26.4%–72.6%CV(PK)) from recovery-related variability only in integral-CA (41.0%–50.3%CV(recovery)). This also led to increased variability of AUC(plasma) for midpoint-CA (56.0%CV) versus midpoint-NCA and integral-CA (≤33.0%CV), and inaccuracy of predictive model performance of midpoint-CA in plasma (visual predictive check). PTA analysis translated into 33% of evaluated patient cases being at risk of incorrectly rejecting recommended dosing regimens at CAP-related epidemiological cut-off values. CONCLUSIONS: Integral-CA proved most appropriate to characterise clinical pharmacokinetics- and microdialysis-related variability. Employing this knowledge will improve the understanding of drug target-site PK for therapeutic decision-making. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11095-021-02994-1.
format Online
Article
Text
id pubmed-7994214
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-79942142021-04-16 Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin Busse, David Schaeftlein, André Solms, Alexander Ilia, Luis Michelet, Robin Zeitlinger, Markus Huisinga, Wilhelm Kloft, Charlotte Pharm Res Research Paper PURPOSE: Systematic comparison of analysis methods of clinical microdialysis data for impact on target-site drug exposure and response. METHODS: 39 individuals received a 500 mg levofloxacin short-term infusion followed by 24-h dense sampling in plasma and microdialysate collection in interstitial space fluid (ISF). ISF concentrations were leveraged using non-compartmental (NCA) and compartmental analysis (CA) via (ii) relative recovery correction at midpoint of the collection interval (midpoint-NCA, midpoint-CA) and (ii) dialysate-based integrals of time (integral-CA). Exposure and adequacy of community-acquired pneumonia (CAP) therapy via pharmacokinetic/pharmacodynamic target-attainment (PTA) analysis were compared between approaches. RESULTS: Individual AUC(ISF) estimates strongly varied for midpoint-NCA and midpoint-CA (≥52.3%CV) versus integral-CA (≤32.9%CV) owing to separation of variability in PK parameters (midpoint-CA = 46.5%–143%CV(PK), integral-CA = 26.4%–72.6%CV(PK)) from recovery-related variability only in integral-CA (41.0%–50.3%CV(recovery)). This also led to increased variability of AUC(plasma) for midpoint-CA (56.0%CV) versus midpoint-NCA and integral-CA (≤33.0%CV), and inaccuracy of predictive model performance of midpoint-CA in plasma (visual predictive check). PTA analysis translated into 33% of evaluated patient cases being at risk of incorrectly rejecting recommended dosing regimens at CAP-related epidemiological cut-off values. CONCLUSIONS: Integral-CA proved most appropriate to characterise clinical pharmacokinetics- and microdialysis-related variability. Employing this knowledge will improve the understanding of drug target-site PK for therapeutic decision-making. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11095-021-02994-1. Springer US 2021-03-15 2021 /pmc/articles/PMC7994214/ /pubmed/33723793 http://dx.doi.org/10.1007/s11095-021-02994-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Paper
Busse, David
Schaeftlein, André
Solms, Alexander
Ilia, Luis
Michelet, Robin
Zeitlinger, Markus
Huisinga, Wilhelm
Kloft, Charlotte
Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin
title Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin
title_full Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin
title_fullStr Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin
title_full_unstemmed Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin
title_short Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin
title_sort which analysis approach is adequate to leverage clinical microdialysis data? a quantitative comparison to investigate exposure and response exemplified by levofloxacin
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994214/
https://www.ncbi.nlm.nih.gov/pubmed/33723793
http://dx.doi.org/10.1007/s11095-021-02994-1
work_keys_str_mv AT bussedavid whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin
AT schaeftleinandre whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin
AT solmsalexander whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin
AT ilialuis whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin
AT micheletrobin whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin
AT zeitlingermarkus whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin
AT huisingawilhelm whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin
AT kloftcharlotte whichanalysisapproachisadequatetoleverageclinicalmicrodialysisdataaquantitativecomparisontoinvestigateexposureandresponseexemplifiedbylevofloxacin